Open AccessCritical need for pharmacologic treatment options in NAFLD: A pediatric perspective
Author(s) -
Friesen Chance S.,
Chan Sherwin S.,
Wagner Jonathan B.,
HoseyCojocari Chelsea,
Csanaky Iván L.,
Shakhnovich Valentina
Publication year - 2021
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12952
Subject(s) - nonalcoholic fatty liver disease , medicine , etiology , perspective (graphical) , obesity , disease , intensive care medicine , intervention (counseling) , clinical trial , liver disease , medline , fatty liver , bioinformatics , gerontology , psychiatry , biology , biochemistry , artificial intelligence , computer science
Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.